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Abstract
Mesenchymal  stem  cells  (MSCs)  are  multipotent  cells  that  can  be  expanded  and
manipulated  ex  vivo.  These  cells  demonstrated  three  biological  characteristics  that
qualify them for the use in cellular therapy: (1) potential of differentiation, (2) secretion
of trophic factors and (3) immunoregulatory properties. The bone marrow (BM) has
been considered as the traditional source of MSCs and much knowledge for potential
clinical applications has been obtained from studies using MSCs derived from adult
bone marrow. MSCs need to be expanded in vitro  for the purpose of cell  therapy.
However, sometimes, the culture expansion could generate cytogenetic and molecu‐
lar alterations. Accumulation of these alterations during many passages of culture could
lead to malignant cell transformation. So, it is important to perform a rigorous control
using different methods to test the safety and efficacy of MSCs for cell therapies. BM-
MSCs have potential clinical applications in haematopoietic stem cell transplantation
(HSCT) as an adjuvant cellular therapy. This chapter reviews the advances in the study
of MSCs and the potential clinical applications of MSCs in haematopoietic stem cell
transplantation (HSCT). We also describe the importance of statistical methods to aid
the analysis of the efficacy and safety for the clinical use of MSCs for HSCT.
Keywords: mesenchymal stem cells, biological characteristics, cell therapy, haemato‐
póietic stem cell transplantation, statistical methods.
1. Introduction
Mesenchymal  stem cells  (MSCs)  are  multipotent  cells  that  can differentiate  in  vitro  into
mesenchymal cell lineages such as adipocytes, osteocytes and chondrocytes. MSCs can be
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expanded and manipulated ex vivo. According to the minimal criteria of the International Society
for Cellular Therapy, MSCs are defined by their growth pattern in vitro (the cultured plastic-
adherent cells), the specific surface antigen expression (CD73, CD90 and CD105, in the absence
of lineage commitment markers such as CD14, CD19, CD34, CD45 and HLA-DR) and multili‐
neage potential (these cells must be able to differentiate into osteoblasts,  adipocytes and
chondroblasts in vitro) [1]. MSCs can be derived from adult bone marrow (BM), adipose tissue
and several fetal tissues as umbilical cord. The bone marrow has been considered as the
conventional source of MSCs and most knowledge for potential clinical applications has been
obtained from studies using MSCs derived from adult bone marrow [2].
MSCs can be expanded and manipulated ex vivo and can demonstrate immunomodulatory
functions in vitro and in vivo. Thus, they represent promising tools to be used in immunore‐
gulatory and regenerative cell therapies. Recently, many studies have revealed the clinical use
of MSCs as an emerging field for treating cardiovascular disorders, neurodegenerative
diseases, bone defects and fractures, inflammatory arthritis and in the field of haematopoiet‐
ic stem cell transplantation (HSCT) [3]. Bone marrow MSCs constitute approximately 0.01%
of mononuclear cells in the bone marrow [4]. Hence, MSCs have to be expanded in vitro on
tissue culture plastic for the purpose of cell therapy. An extensive amplification in vitro is
necessary without affecting the cells’ genomic characteristics and differentiation properties.
But, sometimes, the culture expansion could generate cytogenetic and molecular alterations.
Accumulation of these alterations during many passages of culture could lead to malignant
cell transformation. Hence, it is important to perform a quality control using different methods
to test the safety and efficacy of MSCs for cell therapies.
MSCs generate most of the stromal cells present in the bone marrow (BM). They form part of
the haematopoietic stem cell (HSC) niche and produce various factors regulating haemato‐
poiesis. It has been proposed that BM-MSCs are useful as an adjuvant cellular therapy for
promoting rapid haematopoietic recovery in the HSCT patients. This chapter reviews the
advances in the study of MSCs and the potential clinical applications of MSCs in haemato‐
poietic stem cell transplantation (HSCT). We will also describe the importance of statistical
methods to aid the analysis of the efficacy and safety for the clinical use of MSC for HSCT.
2. Definition and biological characteristics of mesenchymal stem cells
(MSCs)
MSCs were first described in 1966 by Friedenstein and colleagues. They reported the pres‐
ence of fibroblastoid cells that could be obtained from bone marrow of adult mice and when
transplanted subcutaneously, they could differentiate toward osteogenesis [5]. After this
discovery, several studies have been done using human mesenchymal stem cells. These studies
confirmed that it is possible to culture and do sub-passages of the whole bone marrow into
plastic culture dishes and after discarding the non-adherent cells a few hours later, the cells
adhered to the plastic were capable of forming colonies (colony-forming unit: fibroblastic,
CFU-F). It was observed that the MSCs have two important properties. First, they can
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differentiate into distinctive end-stage cell types, including bone, cartilage, muscle, bone
marrow stroma, tendon/ligament, fat, dermis and other connective tissues. Second, MSCs,
themselves, secrete a broad spectrum of bioactive macromolecules that are immunoregulato‐
ry and serve to structure regenerative microenvironments in an injured tissue [6].
MSCs are not only found in bone marrow. MSCs have been isolated from multiple tissues such
as skeletal muscle, adipose tissue, synovial membranes, dental pulp, periodontal ligaments,
cervical tissue, umbilical cord, amniotic fluid and placenta. However, much knowledge
regarding the biological characteristics and clinical experiences has been obtained from studies
of MSCs derived from adult bone marrow [2, 7–9]. MSCs, also known as multipotent cells, are
found in adult tissues of different sources. They are self-renewable, multipotent, easily
accessible, and culturally expandable in vitro [10].
When cultivated in vitro, MSCs have three biological characteristics that qualify them for use
in cellular therapy: (1) potential of differentiation, (2) secretion of trophic factors that help
tissue remodelling and (3) immunoregulatory properties [2]. Therapeutic benefits of MSCs are
dependent on their capacity to act as a trophic factor pool. After MSCs home to damaged tissue
sites for repair, they interact with local stimuli, such as inflammatory cytokines, ligands of Toll-
like receptors (TLRs) and hypoxia, which can stimulate MSCs to produce a large amount of
growth factors that act with multiple functions for tissue regeneration. Many of these factors
are critical mediators in angiogenesis and prevention of cell apoptosis such as vascular
endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1) and IL-6 [11].
Many studies have demonstrated the immunoregulatory properties of MSCs. These cells affect
the immune response through their interactions with the cellular components of the im‐
mune system: T lymphocytes, B lymphocytes, natural killer (NK) cells and dendritic cells
(DCs). MSC immunoregulation can occur through cellular contact and/or by secretion of
diverse factors. Because of these properties, MSCs can prevent the inappropriate activation of
T lymphocytes and generate a tolerogenic environment during repair or stop an immune
response during healing, thus contributing to the maintenance of immune homeostasis [12,13].
Immunomodulatory properties of MSCs can be grouped into three categories: being hypoim‐
munogenic, modulating T cell phenotype and immunosuppressing the local environment [14,
15].
MSCs have decreased the expression of surface molecules including low levels of MHC class
I and costimulatory CD40, CD80, and CD86 and no MHC class II molecules. This distribu‐
tion of surface markers allows MSCs to evade detection from certain immune cells and
contributes to their hypoimmunogenicity. MSCs also have the ability to immunosuppress the
local environment and this can be attributed to their effect on cytokine secretion profiles.
Specifically, in co-cultures with immune cells, MSCs had an indirect effect on T cell matura‐
tion and proliferation by up regulating the secretion of suppressive cytokines (IL-4 and IL-10)
to decrease the secretion of proinflammatory cytokines (TNF-α and IFN-γ) from dendritic cells,
T helper cells and macrophages. MSCs have the ability to induce regulatory T cells, which
ultimately inhibit the proliferation and function of T cells, B cells and natural killer cells. Several
soluble mediators, such as transforming growth factor β1, prostaglandin E2 (PGE2), human
leukocyte antigen G5, haemoxygenase I, nitric oxide, IL-6 and indoleamine 2,3-dioxygenase
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(IDO), are important for this process [13]. Indoleamine 2,3-dioxygenase, which is induced by
IFN-γ, catalyzes the conversion from tryptophan to kynurenine and inhibits T-cell responses
[16,17].
As we can observe, the immunomodulatory characteristics of MSCs are important for cell
therapy. But, approximately 2 × 106 cells/kg are required for clinical application of MSCs [3].
Therefore, for cell therapy, it is necessary to expand the MSCs using culture methods.
2.1. Isolation and culture expansion of MSCs for cell therapy
Clinical protocols employ cell culture technologies that use a small fraction of primary MSCs
isolated from a selected tissue source and expanded by multiple passages in order to gener‐
ate a clinically relevant number of cells. Consequently, once the tissue source of MSCs is
determined for a specific clinical application, the safety and efficacy may be significantly
influenced by cell bioprocessing protocols [18, 19].
There are no standard culture protocols for isolation and expansion of MSCs. Hence, the way
in which these cells are cultured in vitro varies considerably between research groups.
Consequently, it is difficult to compare results from different studies [19–21]. But, the
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
Therapy proposed minimal criteria to define MSCs in vitro: (1) MSCs must be adherent to
plastic under standard tissue culture conditions; (2) MSCs must express certain cell surface
markers such as CD73, CD90 and CD105 and lack expression of other markers including CD45,
CD34, CD14, or CD11b, CD79alpha or CD19 and HLA-DR surface molecules; (3) MSCs must
have the capacity to differentiate into osteoblasts, adipocytes and chondroblasts under in vitro
conditions [1].
The procedures used to isolate MSCs, for example, from bone marrow, usually use density
centrifugation (with Ficoll™, Lymphoprep™ or Percoll™ density mediums) to separate the
mononuclear cell fraction from the other marrow constituents such as red blood cells, plasma
and lipids. This mononuclear cell fraction contains an enriched population of T cells, B cells,
monocytes, hematopoietic stem cells (HSCs), endothelial progenitor cells and MSCs. Following
plating onto tissue culture flasks, MSCs, which represent the adherent cell population, form
colonies. The adherent cells remain in culture and the other non-adherent cells are discarded
while changing the medium [19, 21]. The MSCs are anchorage-dependent cells that expand
when maintained in culture conditions such as medium DMEN supplemented with 10% of
FBS. Initial growth of MSCs in primary BM cell culture on a plastic surface is characterized by
the formation of single cell-derived colonies. The efficiency with which they form colonies still
remains an important assay for the quality of cell preparations. In general, MSCs have a great
propensity for expansion in culture, although their proliferation potential is highly variable,
mainly between young and older donors who retain reduced proliferative potential [19,22].
MSCs seeding densities range between 2.000 and 5.000/cm2; however, there is evidence that
lower seeding densities enhance proliferation, which is thought to be attributed to a reduc‐
tion in contact inhibition. Some studies demonstrated that MSCs proliferate more rapidly when
passaged by plating the cells at low densities as 10–100 cells/cm2 [19, 23, 24]. MSCs are most
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commonly expanded in a basal media such as Dulbecco’s modified Eagle’s medium (DMEM)/
DMEM F-12 or alpha-MEM with 10% fetal bovine serum (FBS) [21]. All current protocols for
in vitro culture of MSCs include FBS as a nutritional supplement [25]. However, some problems
are associated with the use of FBS, for example, risk of contamination associated with harmful
pathogens such as viruses, mycoplasma, prions or unidentified zoonotic agents. The chance
of contamination or immunological reaction towards xenogeneic compounds must be also
taken into consideration [19, 26]. Hence, for using FBS, tests are necessary for providing
optimal growth conditions [21].
Successful expansion techniques aim to facilitate significant increases in cell number with‐
out affecting the MSC therapeutic potential. MSCs can be cultured in vitro for 8–15 passages,
corresponding to approximately 25–40 population doublings and 80–120 days. MSCs demon‐
strate a marked decrease in proliferation as a function of duration in culture and passage
number, thereby becoming senescent and ceasing to proliferate [4, 7, 27]. MSCs may lose
differentiation capacity during the time in culture to assess multilineage potential. The potency
of MSCs rapidly decline as a function of 2D expansion and this shows a demand for alterna‐
tive expansion techniques [4].
Bone is a 3D substrate composed of water, organic collagen and inorganic hydroxyapatite.
MSCs reside within crevices of the blood-submerged bone and among several cell types with
which they engage in a complex orchestra of crosstalk. Numerous aspects of the bone marrow
niche, which regulate MSC behavior, are absent in 2D culture. Hence, it is necessary to develop
new techniques to recreate characteristics of the elaborate niche to preserve MSC progenitor
potency through 3D expansion [4, 28–30]. Some studies have been demonstrated that MSCs
can be expanded using scaffolds or scaffoldless approaches, usually in combination with a
bioreactor. 3D MSC expansion has been performed on hydroxyapatite (HA), chitosan gelatin
and HA/chitosan gelatin and gelatin microcarriers [4, 28, 31].
Bioreactors are devices that facilitate the development of biological and/or biochemical
processes through operating parameters such as pH, temperature, nutrient supply and waste
removal. Bioreactor systems are essential tools to achieve the goals in the clinical-scale
expansion and tissue engineering applications [4]. They maintain the minimal criteria to define
MSCs, which include plastic adhesion, expression of a set of specific surface markers and the
ability of differentiation along osteogenic, adipogenic and chondrogenic lineages [1]. MSCs
also bear broad regenerative and trophic activities, including the secretion of extracellular
matrix (ECM), pro-mitotic and pro-angiogenic factors, anti-inflammatory and immune-
regulatory factors, and other bioactive molecules that stimulate tissue regeneration by
reconstructing a pro-regeneration microenvironment and by modulating immune and
inflammatory responses. Thus, these unique properties play a central role to the success of
MSC-based therapeutic applications [32–34].
2.1.1. Multilineage potential
MSCs have the potential for multilineage differentiation. This property has been studied for
the development of MSC transplantation as a regenerative therapy. Multilineage potential is
a criterion to define the MSCs in vitro. The multilineage potential may be observed under
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culture conditions that induce cell differentiation into three lineages: osteogenic, adipogenic
and chondrogenic [35]. A number of in vitro assays can be used to assess the multipotentiali‐
ty of these cell preparations. Osteogenic differentiation of MSCs can be induced using
dexamethasone, ascorbate-2-phosphate and beta glycerolphosphate. Osteoblasts may be
identified using alizarine red S staining. Adipogenic differentiation can be induced with the
medium containing dexamethasone, indomethacin, isobutylmethylxanthine and insulin. Oil
red O staining may be used to detect lipid accumulation. Chondrogenic differentiation can be
induced in a defined medium containing dexamethasone, ascorbate-2-phosphate, insulin,
selenious acid, transferrin, sodium pyruvate and transforming growth factor-beta [3, 36, 37].
The ability of MSCs to differentiate along these lineages is strongly associated with their
multipotency and stem cell nature. However, MSCs do not maintain these characteristics
indefinitely and MSCs senescence with extensive subcultivation in vitro whereby they lose
their proliferation and differentiation potential [37]. Such culture expansion could also
generate genetic and epigenetic instability, including chromosome alterations. The accumu‐
lation of genetic changes during cell culturing and subsequent risk of cell transformation are
other important points of stem cell therapy [3, 38].
2.1.2. Cytogenetic and molecular characteristics of MSCs
The utilization of MSCs for cell therapy requires large-scale in vitro expansion, thus increas‐
ing the probability of cytogenetic and molecular instabilities [38]. The expansion of MSCs in
culture could generate chromosomal abnormalities such as aneuploidy (the presence of an
abnormal number of chromosomes in a cell) or structural chromosomal alterations, reflect‐
ing the chromosomal instability. But, it is not clear how many passages can be performed before
these cells acquire chromosome instability or lose their multipotency [3, 39, 40]. Some studies
have been shown that in vitro culture of MSCs from bone marrow and adipose tissue re‐
tained normal karyotypes between passages 1 and 5 [3, 39, 41]. At later passage cultures, MSCs
began to show chromosomal abnormalities such as aneuploidy. However, other studies
observed that MSC cultures derived from bone marrow and adipose tissue had normal
karyotypes up to passage 20 [42, 43]. Although these results are debatable, they show the
necessity of cytogenetic analyses for safety before therapeutic application of mesenchymal
stromal cells.
Molecular studies also have an important role to determine appropriate MSCs to be used for
cell therapy. All primary human cells, including MSCs, undergo only a limited number of cell
divisions under standard culture conditions, in a process called cellular senescence. Senes‐
cence is considered to be a stress response triggered by activation of some mechanisms as
telomere erosion and accumulation of DNA damage [44, 45]. In vitro cultures cause signifi‐
cant telomere shortening. Telomeres are the termini of eukaryotic chromosomes and their
principal function is to protect chromosomes from illegitimate fusion and recombination,
thereby preserving genome integrity [45, 46]. Since MSCs have only a finite ability for self-
renewal like most somatic cells, assaying for telomere length in hMSCs provides critical
information on the replicative capacity of the cells, an important criterion in the selection of
MSCs for therapy. Telomere length is generally quantified by Southern blotting and fluores‐
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cence in situ hybridization and more recently by polymerase chain reaction (PCR)-based
methods [47].
The multipotency of MSCs has allowed a significant progress in our understanding about
differentiation pathways of various lineages for tissue engineering and therapeutic purposes
[48]. Runt-related transcription factor 2 (Runx2) has been considered as a master regulatory
gene responsible for early osteogenic differentiation [49]. While Runx2 acts to promote
osteoblastic differentiation, another important osteogenic inducer, osterix, suppresses
chondrogenesis and promotes osteoblastic differentiation at a later stage. Low levels of osterix
are sufficient to inhibit chondrogenesis, while a high expression level is necessary for
osteogenic differentiation [48, 50]. Furthermore, ex vivo MSCs have successfully differentiat‐
ed into osteoblasts in osteogenic media supplemented by dexamethasone and ascorbate. The
selective capability to promote osteogenic differentiation has potential clinical implications in
bone repair and regeneration [48, 51].
In-vitro differentiation of MSCs into a chondrogenic lineage has been studied through exposure
to growth factors, co-culture with cartilage and overexpression of specific genes such as SRY-
box 9 (Sox9) to promote chondrocytic differentiation. Sox9 cooperates with its downstream
proteins Sox5 and Sox6 to promote chondroycte proliferation and maturation and matrix
formation [48, 52]. MSCs also have the capacity to differentiate into an adipogenic lineage.
PPAR-γ plays a critical role in this process by regulating the function of many adipocyte-
specific genes. In addition, PPARγ interacts with members of the CCAAT/enhancer-binding
protein (C/EBP) family to regulate adipogenesis. Cells can also be induced to undergo
adipogenesis through exposure to exogenous factors or by culturing them in adipogenic media
containing insulin and dexamethasone [48, 53]. As the multilineage potential is one of the three
criteria to define the MSCs in vitro according to the International Society of Cellular
Therapy [1], the use of molecular tests to analyze the expression of the genes involved in the
differentiation of the osteogeneic, chondrogenic and adipogenic are important to associate the
biological function of the MSCs for their clinical use.
The expansion of MSCs in vitro is associated with genetic instability. Hence, molecular studies
comparing the molecular profile during the culture passages are important to acquire
knowledge about molecular modifications and potential risks for cell therapy. In this sense,
proteomic and transcriptomic approaches have been used to verify molecular modifications
of MSCs from different culture passages [3, 54].
We need to be careful before using BM-MSCs for clinical applications. Some changes may be
analyzed such as enlarged morphology, decreased number of cell divisions, random loss of
genomic regions and telomere shortening. These modifications process could lead to a
reduction in the multipotent state of MSCs and might lead to tumour formation under specific
conditions. It is very important to characterize the cytogenetic and molecular profiles during
expansion in vitro of BM-MSCs; thus, appropriate tests should be applied to ensure the integrity
of the genome and epigenome [54].
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2.1.3. Quality control for cell therapy
There are many challenges associated with characterizing and quantifying cells for use in cell-
and tissue-based therapies. From a regulatory perspective, these advanced treatments must
not only be safe and effective, but also must be made by high-quality manufacturing process‐
es [55]. Prolonged exposure to stressful conditions during the cell enrichment and differen‐
tiation processes has raised concerns about the safety of stem cell therapy. The International
Society for Stem Cell Research has created “Guidelines for the Clinical Translation of Stem
Cells” [56]. Some cytogenetic tests that may be performed to ensure the safety of the stem cells
include: G-banding, fluorescence in situ hybridization (FISH) and array comparative genom‐
ic hybridization (array CGH) [38, 57]. Molecular genetic tests may be performed as the analysis
of the telomere length, the expression of genes involved in the osteogenic, adipogenic and
chondrogenic differentiation. Some characteristics and tests, which may be considered as a
quality control for the use of MSCs for cell therapy, are shown in Figure 1. The practical
application of these recommended tests can be standardized for the sensitivity and specifici‐
ty between laboratories.
Figure 1. Some characteristics and tests that may be considered as a quality control for the use of MSCs for cell thera‐
py.
The first clinical trial using culture-expanded MSCs was performed in 1995 and bone mar‐
row samples were obtained from 23 patients with haematologic malignancies in complete
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remission. In this study, as no adverse reactions were observed with the infusion of the MSCs,
Lazarus and colleagues concluded that MSCs obtained from cancer patients can be collected,
expanded in vitro and infused intravenously without toxicity [58]. Many completed clinical
trials have demonstrated the efficacy of MSC infusion for diseases including acute myocar‐
dial ischaemia, liver cirrhosis, amyotrophic lateral sclerosis and graft versus host disease
(GVHD) [12, 59]. The statistical methods are important tools to evaluate the quality, safety and
efficiency of MSCs for cellular therapy as we will observe in the last section.
3. Potential clinical applications of MSCs in haematopoietic stem cell
transplantation
Haematopoietic stem cell transplantation (HSCT) is the first field wherein human stem cell
therapy was successful. Allogeneic HSCT has been an important modality to cure various
diseases, including haematologic malignancies, various non-malignant haematologic diseas‐
es and primary immunodeficiency diseases. However, autologous HSCT is generally per‐
formed to rescue bone marrow aplasia following high-dose chemotherapy for solid tumour
or multiple myeloma [60].
The first successful HSCT using bone marrow from a relative donor was performed in 1968 in
a boy with X-linked severe combined immunodeficiency disease (SCID). Since the first
successful achievement in human, numerous trials and errors were repeated until 1980, when
allogeneic HSCT began to be actively performed under a better recognition of transplant
immunology. Dr. Donnall Thomas received Nobel Prize for his pioneering work in bone
marrow transplantation to cure leukaemia and other haematologic malignancies [60].
Results from basic and clinical research have allowed the improvement of HSCT. Some of these
improvements were the use of haematopoietic stem cells from peripheral blood or cord blood,
which promoted a change in the terminology from bone marrow transplantation to haemato‐
poietic stem cell transplantation [61]; a better understanding of the complexities of the human
leukocyte (HLA) system, which has allowed selecting compatible sibling donors and the
establishment of larger registries of HLA-typed volunteers; advances in the immunogenetics
of HLA, especially typing of molecular techniques; the development of the preparative
regimen of cyclophosphamide and busulfan, which avoids the use of irradiation for some
diseases [62]; the development of non-myeloblative conditioning regimens for allogeneic
HSCT, avoiding regimen-related toxicity and death and that opened the way to include elderly
patients [61, 63].
These advances make HSCT one curative treatment modality for many patients mainly with
malignant haematological diseases. But, remaining challenges include further advances in the
prevention and treatment of both infections and graft-versus-host disease (GVHD). Despite
significant progress in HSCT, GVHD remains a significant cause of morbidity and mortality
after allogeneic HSCT [63–67].
Homeostasis of the haematopoietic system, which is a balance between self-renewal and
differentiation, is thought to be tightly regulated by interactions among haematopoietic stem
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cells (HSCs) and the specialized microenvironment where they reside, the haematopoietic
niche. The haematopoietic niche consists of a heterogeneous cellular population of non-
haematopoietic and haematopoietic origin as well as of extracellular matrix, which collective‐
ly provide the structural scaffold, the spatial framework and the appropriate physiological
and trophic cues to control HSC maintenance and function [68]. The key component of the
haematopoietic microenvironment is bone marrow mesenchymal stromal cells (BM-MSCs).
Many studies have reported that MSCs can promote HSC expansion in vitro. Koc and
colleagues (2000) first reported rapid haematopoietic recovery after co-infusion of autolo‐
gous BM-MSCs at the time of HSCT without significant side effects [69]. Lazarus and collea‐
gues (2005) showed, in a multicenter trial with 46 patients receiving allogeneic HSCT and MSCs
from HLA-identical siblings, a rapid haematopoietic recovery in most patients [58]. These
studies showed the beneficial effects of MSC on engraftment after HSCT [2].
BM-MSCs have potential clinical applications in HSCT as an adjuvant cellular therapy for
promoting the rapid reconstitution of haematopoiesis after HSCT, to prevent and treat of graft
failure, in graft versus tumour effect and in GVHD [2, 70].
3.1. Pathophysiology of graft-versus-host disease (GVHD) and clinical use of MSC for
GVHD
Allogeneic HSCT is an effective treatment for many haematologic and genetic diseases.
However, donor-derived cells may also recognize recipient organs as foreign and mount an
immune attack against the patient’s own tissues, knows as graft-versus-host disease (GVHD)
[71].
Graft-versus-host disease (GVHD) is the major cause of morbidity and mortality after an
allogeneic HSCT. GVHD has traditionally been classified by the time of its clinical manifesta‐
tions. Acute GVHD occurs within the first 100 days after haematopoietic stem cell transplan‐
tation, whereas chronic GVHD occurs after day 100. This simple classification is increasingly
unsatisfactory particularly as reduced-intensity condition regimens gain wider acceptance.
The clinical manifestations of acute GVHD after such conditioning often occur much later,
sometimes coinciding with the day 100, the demarcation of chronic GVHD [72]. New recom‐
mendations that emphasize the importance of qualitative differences, as opposed to the time
of onset after HSCT, are being used to standardize the diagnosis and clinical assessment of
chronic GVHD [73].
The pathophysiology of acute GVHD after HSCT can be considered as a three-step process
where the innate and adaptive immune system interacts. These three-step processes are as
follows: (1) initiation of tissue damage; (2) activation and proliferation of donor T cells; and
(3) the effector phase involving cellular and inflammatory factors. The pathophysiology of
GVHD is a complex process. Chemotherapy and radiation cause tissue damage, producing
pro-inflammatory cytokines, resulting in donor T-cell activation through the host antigen-
presenting cell (APC) interaction via MHC-T cell receptor binding and co-stimulatory signals.
This leads to T cell expansion and differetiation into various subtypes which traffic through
blood vessels to target organs, where they cause tissue destruction and recruitment of other
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inflammatory cells through pathways such as perforin/grazyme and cytokine release.
Moreover, these inflammatory cells and cytokines can propagate the cycle of GVHD [71, 72,
74]. The main step of GVHD reaction is step 2, where donor T cells are activated by the host
antigen-presenting cells (APCs). The GVHD reaction is amplified by the intensity of the
recipient-conditioning regimen, which can result in an intensive tissue damage with the release
of various cytokines and augment of inflammatory response [75].
Acute GVHD affects mainly skin, liver and gastrointestinal tract. Approximately 50% of the
patients treated with HSCT subsequently developed acute GVHD and required systematic
treatment. Chronic GVHD occurs in 40% of patients treated with allogeneic HSCT from HLA-
identical sibling and more than 50% of patients treated with HSCT from an HLA non-identical-
related donor [67, 75].
Chronic GVHD is one of the most significant complications of long-term survivors after
allogeneic haematologic stem cell transplantation. Experimental studies and clinical observa‐
tions have elucidated the mechanisms of acute GVHD, but the biology of chronic GVHD is not
well understood. Experimental studies generated at least four theories to explain the patho‐
physiology of chronic GVHD: (1) thymic damage and the defective negative selection of Tcells;
(2) regulatory T cells deficiences; (3) auto-antibody production by aberrant B cells; and (4) the
formation of profibrotic lesions [73]. The immunopathology of chronic GVHD is mediated in
part by helper T lymphocyte 2 (Th2) cells, with a syndrome of immunodeficiency and an
autoimmune disorder [76].
GVHD remains associated with significant morbidity and mortality in allogeneic HSCT.
Improving outcomes in HSCT will require additional therapeutic modalities such as the use
of MSCS. MSCs may be used to modulate the immune system, as prophylaxis to prevent
GVHD and as treatment for established GVHD. Some studies have been performed demon‐
strating that the MSCs can act in GVHD [76–81]. In a multicenter clinical trial, HSCs and MSCs
derived from HLA-identical sibling donors were infused and promoted haematopoietic
engraftment and limited GVHD. In this study, 31 patients received myeloblative conditionig
and HLA-identical sibling bone marrow or peripheral blood stem cells. Escalating doses of
MSCs from 1 to 5 x106/kg were given. Toxicity related to MSC infusion was not observed. The
incidence of acute GVHD was 15% in the co-transplanted group compared with 40% in a
matched control group [17, 77]. Le Blanc and colleagues (2004) reported a child with acute
lymphoblastic leukaemia receiving haploidentical MSC infusion for severe acute GVHD with
a satisfactory clinical outcome [78]. The immunomodulatory abitily of BM-MSCs shows
promise in treating GVHD, especially acute GVHD. Zhou and colleagues (2010) also showed
the potential clinical application of MSCs for chronic GVHD. In this study, four patients with
sclerodermatous chronic GVHD were reported, who received MSCs expanded ex vivo from
unrelated donors by intra BM injection. After MSC infusion, the symptoms gradually
improved in all four patients. During the course of MSC treatment, the patient’s vital signs
and laboratory studies remained normal. None of the four patients had recurrence of leukae‐
mia. This study, despite its limited number of patients, suggests a benefit of MSC infusion
therapy in treating sclerodermatous chronic GVHD [76]. MSCs are capable of escaping
recognition by the alloreactive immune system and can exert immunomodulatory and anti-
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inflammatory effects. Hence, these cells represent a promising tool in the prevention and
treatment of GVHD [2].
3.2. Prevention and treatment of graft failure using MSC
Graft failure or graft rejection after HSCT may occur as either a lack of initial engrafment of
donor cells or loss of donor cells after initial engraftment. In the later case, autologous recovery
may appear or, alternatively, marrow aplasia may be developed. Rejection is a major cause of
graft failure and it is due to recipient immune response against donor Immuno-haematopoiet‐
ic cells. Graft failure may also occur to other causes, such as viral infections, specifically,
cytomegalovirus (CMV) [82]. In patients with leukaemia receiving myeloblative condition‐
ing, the rejection rate was 0.1% in patients given HLA-identical sibling transplants com‐
pared to 5% in those given HLA-mismatched grafts. Another risk factor for graft failure is the
reduced intensity conditioning that is used in the elderly patients, with lower doses of chemo-
radiation therapy, the host immune system may persist, resulting in an increased risk of
allograft rejection. Hence, the main risk factors associated with graft failure include HLA
disparity in the donor/recipient pair, viral infections and the type of conditioning regimen [82,
83].
Some studies have demonstrated that the use of MSCs is efficient in prevention and treat‐
ment of graft failure [2, 9, 70]. Ball and colleagues carried out a pilot study of co-transplant‐
ed of BM-derived, ex vivo-expanded MSCs of donor origin in 14 children undergoing
transplantation of granulocytic colony stimulating factor (G-CSF) mobilized, CD34-selected
progenitor cells from HLA disparate relative. In this study, a graft failure rate of 15% was
observed in 47 controls and all patients, who received MSCs, showed sustained haemato‐
poietic engraftment without any adverse reaction. These results suggested that MSC co-
transplantation may modulate host alloreactivity and/or promote better engraftment of donor
haematopoiesis, thus reducing the risk of graft failure [9].
3.3. Graft-versus-tumour effect and MSCs
Two mechanisms are involved in the cure of a malignant disease by stem cell transplanta‐
tion. The first is the conditioning regimen, which confers a powerful anti-tumour effect from
myeloblative doses of chemotherapy or radiotherapy. The second is the graft-versus-leukae‐
mia (GVL) effect or the graft-versus-tumor (GVT) effect exerted by transplanted donor T cells
and NK cells against malignant tissue. The T lymphocytes recognize antigens presented by
HLA molecules on malignant cells. They destroy tumour cells by direct cytotoxicity induc‐
ing death by lysis though the perforin-granzyme pathway and by apoptosis though activa‐
tion of Fas on the cell surface. The graft-versus leukaemia effect requires donor immune
competence that often accompanies graft-versus-host disease (GVHD) [84].
Despite HLA identity between a patient and donor, approximately 40% of patients receiving
HLA-identical grafts develop acute GVHD due to genetic differences that lie outside the HLA
loci, or minor histocompatibility antigens (HA). Some of such antigens, such as HY and HA-3,
are expressed on all tissues and are targets for both GVHD and GVL. Others, such as HA-1
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and HA-2, are expressed most abundantly on haematopoietic cells (including leukaemic cells)
and may therefore induce a greater GVL effect with less GVHD [75].
Bearing in mind two fundamental aspects to the success of allogeneic HSCT, the GVL effect
and the GVHD, the co-infusion of MSCs in transplantation should aim at reducing the severity
of GVHD while preserving the GVL. In this sense, the study of Baron and colleagues (2010)
demonstrated that the MSC co-infusion appeared to be safe; furthermore, MSC co-infusion
might have prevented death from GVHD without abrogating GVT effects. In this study, 20
patients with haematologic malignancies received MSCs from HLA-mismatched donors after
conditioning with TBI (total body irradiation) and fludarabine. The HLA-mismatched non-
myeloblative HSCT with MSC co-infusion had a therapeutic effect on the haematologic
malignancies. MSCs may have important beneficial characteristics in terms of promoting GVT
effects due to their immunomodulatory properties after HSCT and their tropism towards the
microenvironment [85, 86]. Figure 2 shows the potential clinical applications of MSCs for
haematopoietic stem cell transplantation.
Figure 2. Potential clinical applications of MSCs for HSCT.
4. Using probability techniques to study clinical applications of
mesenchymal stem cells
Nowadays, people recognize the importance of Mathematics in Medicine. Many statements
in this area can be better understood using mathematical concepts and results. In this section,
we will present mathematical techniques based on the concept and results of probability, as
we are interested in making decisions in the face of uncertainty. In fact, in Medicine, clinical
outcomes, such as the occurrence of disease, death, symptoms or functional impairment, can
be counted and expressed as numbers, but in most clinical situations, the diagnosis, progno‐
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sis and treatment outcomes are uncertain for an individual patient. A person will experience
a clinical outcome or not: the prediction is rarely exact. Therefore, the prediction must be
expressed as a probability.
Although earlier work on probability was done by the Italian mathematician Giralamo
Cardano (1501–1576), the investigation of probability as a branch of Mathematics sprang
about 1654 with two great French mathematicians: Blaise Pascal (1623–1662) and Pierre
Fermat (1601–1665) [87]. Of course, we shall not do a discourse on probability. But, we need
to say that the theory of probability underlies the procedures in testing hypotheses, which are
very useful to Medicine and other disciplines in the health field.
In this section, we will avoid mathematical formulas and theorems.
4.1. Descriptive statistics and inferential statistics
Statistics is a branch of Mathematics. The word “statistics” derives from the Latin word status,
meaning “manner of standing” or “position.” Statistics were first used by tax assessors to
collect information for determining assets and assessing taxes. Statistics applied to Medicine
and other health disciplines is called biostatistics or biometrics. For those who would like to
study this subject, we recommend the book of J. H. Zar [88].
Statistics is divided into two branches: descriptive and inferential. Descriptive statistics is used
to organize and summarize data. Inferential statistics is used to draw inferences and reach
conclusions about a population, when only a sample from that population has been studied.
A population is a complete set of observations, patients, measurements and so forth. A sample
is a subset of a certain population.
The mathematical techniques used on descriptive statistics are graphic (tables and graphs) and
numerical (quantitative indices). Tables are often used to present qualitative and quantitative
data. Graphs are used widely to provide a visual display data. The bar diagram, histogram
and frequency polygon are three graphic formats that are commonly used to present medi‐
cal data. Quantitative indices are numbers that describe the centre and the variation of a
distribution, which are called parameters if they are referred to a population and called statistics
if they are referred to a sample. Quantitative indices that describe the centre of a distribution
are referred to as measures of central tendency. The mean, known also as the arithmetic mean,
median and mode are three common measures of central tendency. Quantitative indices that
describe the variation or dispersion of a distribution are referred to as measures of dispersion.
The range, variance and standard deviation are three common measures of dispersion. Other
quantitative indices such as risk difference, relative risk and odds ratio are also used in
Medicine.
One mathematical technique used on inferential statistics is hypothesis tests. They are much
more sophisticated than the techniques used in descriptive analysis, because hypothesis tests
are based on probability models.
A probability model for a particular experiment is a probability distribution that predicts the
relative frequency of each outcome if the experiment is performed a large number of times. A
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probability distribution is a table, a graph or a formula that describes what probably will happen
instead of describing what really happened.
A probability distribution can be discrete or continuous. An important example of a discrete
probability distribution is the binomial distribution and an important example of a continuous
distribution is the normal distribution.
4.2. Hypothesis tests
A hypothesis test is a method used to determine if there is enough evidence in a sample to
infer that a certain property holds for the entire population. It works with two hypothesis: the
null hypothesis (designated H0) and the alternative hypothesis (designated HA).
In the null hypothesis we use the words no difference or equal to and in the alternative hypoth‐
esis we use the words different from, less than or greater than. But let us mention that, in fact, we
should say no statistical difference, statistically equal to, statistically different from, statistically less
than or statistically greater than, because we are dealing with the probabilities of an event
happens or not. When we retain HA (equivalently reject H0), we say the results are signifi‐
cant and when we retain H0 (equivalently reject HA), we say the results are not significant.
Because we are dealing with probabilities, this implies in making two possible errors from four
possible relations between the conclusions obtained using a hypothesis test and real situa‐
tions, as shown in Table 1.
Real difference
Presence Absence
Conclusion of the statistical test Results are significant True Type I error
Results are not significant Type II error True
Table 1. Relations between statistical conclusions and real situations.
The two errors mentioned in the previous paragraph are known as Type I error and Type II
error. A Type I error leads to a false positive conclusion. The probability of such an error occurs
is noted by α. Mathematically, α is a conditional probability: α is the probability of reject H0
when there is no real difference. A Type II error leads to a false negative conclusion. The
probability of such an error occurs is noted by β. Mathematically, β is a conditional probabil‐
ity: β is the probability of retain H0 when there is a real difference.
Hypothesis tests are used to estimate the probability of a Type I error. So, they are based on
probability models. In the literature, we usually use α < 0.05. This means we are assuming a
probability less than 0.05 of rejecting H0 when there is no real difference between treatments,
drugs or procedures. In other words, if the study were repeated one-hundred times, we
probably would find five outcomes showing H0 should be accepted.
The hypothesis tests commonly used in the medical literature are presented in Table 2. They
can be parametric or nonparametric. The choice in using one of them depends on the pur‐
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pose of the study, the size of the sample and the type of the variables involved at the study,
for instance. If we can guarantee that the sampling distribution is normal or approximately
normal, we can use a parametric test. Because a normal distribution has good mathematical
properties (bell-shaped, symmetric, and so on), using a parametric test leads to better results
compared with a nonparametric test. In other words, we say that nonparametric tests are less
powerful, in the sense that, they lead to a small probability to reject H0, when H0 is false.
To test the statistical significance of the difference between …
Two or more proportions Chi-square Nonparametric
Two proportions Fisher’s exact Parametric
Two medians Mann–Whitney Nonparametric
Two means Student’s t Parametric
More than two means Kruskal–Wallis (one-factor) Nonparametric
More than two means ANOVA (one-factor) Parametric
More than two means ANOVA (more factors) Parametric
Table 2. Statistical tests usually used in the medical literature.
When we use a hypothesis test, we compute a p-value. The p-value is the probability of
obtaining a result as extreme or more extreme than the sample value, assuming that the null
hypothesis is true. The sample value is calculated. Depending on the test we use, there is a
specific formula to calculate the sample value. An appropriate computer software can do such
a calculation.
We finish this subsection noting that many methods described above are univariate meth‐
ods, because they are only concerned with analyzing only one variable. The point in using a
multivariate analysis is to consider several variables simultaneously in the study. With
multivariate methods, we can reduce data information, we can classify objects or variables, we
can investigate the dependence among variables and, finally, we can make predictions.
Principal component analysis, factor analysis and clustering methods can be used in order to
reduce data and investigate the dependence among variables. To make predictions, we can
use Hotelling’s T2 test, which allows inference about one mean vector, and we can use
MANOVA, which allows inference about a finite number of mean vectors. It is important to
say that both Hotelling’s T2 test and MANOVA are generalizations of Student t-test and
ANOVA, respectively. So, they are based on the multivariate normal distribution. For those
who would like to study this subject, we recommend the book of R.A. Johnson and D.W.
Wichern [89].
4.3. Probability techniques on the study of mesenchymal stem cells
In cellular therapy, safety remains one of the main characteristic and refers to validation tests.
The culture process should be reproducible, robust and efficient. The increasing use of MSCs
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has led to a production of processes which needs to be in accordance with current Good
Manufacturing Practice (cGMP) [90, 91]. For the validation of the tests, it is important to use
probability techniques comparing the results of the tests and the results between different
laboratories, with the main to standardize the procedures to characterize the MSCs at the stage
of production for cell therapy. The evidence of clinical efficacy is also required. In this case,
the application of probability methods is also an important tool in clinical trials and clinical
outcomes revealing the impact on the use of MSCS in cellular therapy.
5. Conclusion
Mesenchymal stem cells (MSCs) represent promising tools to be used in immunoregulatory
and regenerative cell therapies. For this purpose, an extensive amplification in vitro of MSCs
is necessary without affecting the cells’ genomic characteristics and differentiation proper‐
ties. However, sometimes, the culture expansion could generate cytogenetic and molecular
alterations. Accumulation of these alterations during many passages of culture could lead to
malignant cell transformation. Hence, it is important to do a quality control using different
methods to test the safe and efficacy of MSCs for cell therapies. Many studies have revealed
the clinical use of MSCs as an emerging field for treating cardiovascular disorders, neurode‐
generative diseases, bone defects and fractures, inflammatory arthritis and in the field of
haematopoietic stem cell transplantation. The BM-MSCs have potential clinical applications
in HSCT as an adjuvant cellular therapy for promoting the rapid reconstitution of haemato‐
poiesis after HSCT, to prevent and treat of graft failure, in graft-versus tumor effect and in
GVHD. Although these studies showed positive results, it is necessary to continue the scientific
and clinical research to clarify some points as: the characterization of the appropriate cell
passage during the culture of MSCSs to ensure the genomic stability; the definition of the tests
for quality control to ensure the safety of the MSCS for clinical practice; the practical applica‐
tion of these recommended tests can be standardized for the sensitivity and specificity between
the laboratories; it is necessary to define the optimum cell dose and the number of infusions
of MSCs during the treatment; a long follow-up to characterize the positive clinical effects and
also the adverse clinical effects that may occur with the use of MSCs. With the advancement
of basic and clinical research, we hope that the use of MSCs in cell therapy brings excellent
results especially for patients treated with HSCT.
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